Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25707336 | 0.90 | HTR2A (0.59) | HTR2AHTR2C | |
| SCHEMBL25244513 | 0.88 | HTR2A (0.58) | HTR2ASMN1; SMN2HTR2CTAAR1POLB | |
| SCHEMBL25424120 | 0.85 | HTR2A (0.67) | HTR2ASMN1; SMN2HTR2CTAAR1POLB | |
| SCHEMBL25706938 | 0.84 | HTR2A (0.65) | HTR2ASMN1; SMN2HTR2CTAAR1MTNR1A | |
| SCHEMBL31307673 | 0.84 | HTR2A (0.65) | HTR2ASMN1; SMN2HTR2CTAAR1MTNR1A | |
| SCHEMBL25706441 | 0.84 | HTR2A (0.65) | HTR2ASMN1; SMN2HTR2CTAAR1POLB | |
| SCHEMBL25239250 | 0.84 | HTR2A (0.65) | HTR2ASMN1; SMN2HTR2CTAAR1POLB | |
| SCHEMBL24163782 | 0.84 | HTR2A (0.57) | HTR2ASMN1; SMN2HTR2CTAAR1POLB | |
| SCHEMBL25282189 | 0.83 | HTR2A (0.63) | HTR2ASMN1; SMN2HTR2CTAAR1POLB | |
| SCHEMBL25707338 | 0.82 | HTR2A (0.52) | HTR2AHTR2CTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR2A 37/4885SMN1; SMN2 405/4885ALDH1A1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.